A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + IMRT for Locally Advanced Non-Metastatic SCC of the Oral Cavity/Oropharynx
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society